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Sinmary To test the hypothesis that high levels of endogenous oestrogens increase the risk for developing
breast cancer, concentrations of oestrone, oestradiol and oestriol were measured in 24 h urine samples from
1000 women partipants in a prospective study of breast cancer on the island ofGuersey. Sixty-nine subjects
were diagnosed with breast cancer subsequent to urine collection. Among women who were premenopausal at
the time of urine collection, cases excreted less oestrogen than controls; the odds ratios (95% Cl) for breast
cancer in the middle and upper thirds of the distribution of oestrogen excretion, in comparison with the lower
third (reference group, assigned odds ratio= 1.0), were 0.5(0.2- 1.2) and 0.4(0.2- 1.1) respectively for oestrone,
0.8(0.4-1.8) and 0.4(0.2-1.1) for oestradiol, 0.7(0.3-1.6) and 0.7(0.3-1.6) for oestriol and 0.9(0.4-2.0) and
0.5(0.2-1.3) for total oestrogens. Among women who were post-menopausal at the time ofurine collection, the
trend was in the opposite direction, with an increase in risk associated with increased oestrogen excretion; the
odds ratios were 0.9(0.3-2.2) and 1.1(0.5-2.8) for oestrone, 0.8(0.3-2.3) and 1.9(0.8-4.6) for oestradioL
1.5(0.6-3.9) and 1.8(0.7-4.6) for oestriol and 0.9(0.4-2.6) and 1.9(0.7-4.7) for total oestrogens. The trends of
increasing risk with increasig oestrogen excretion among post-menopausal women were statistically significant
for oestradiol (P=0.022) and for total oestrogens (P=0.016). We conclude that high levels of endogenous
oestrogens m post-menopausal women are associated with increased breast cancer risk, but that the
relationship of oestrogens in premenopausal women with risk is unclear.
Keywords urinary oestrogen; breast cancer risk; prospective study
The hypothesis that high levels of endogenous oestrogens
may increase breast cancer risk has existed for at least 30
years, but has still not been firmly established. In a review of
32 studies published up until 1987, we concluded that post-
menopausal breast cancer cases are exposed to more
endogenous oestrogen than controls (Key and Pike, 1988),
and more recent studies have in general supported this
conclusion. In two small case-control studies, Bernstein et
al. (1990a) and Zaridze et al. (1992) reported higher
oestradiol levels in cases than in controls among post-
menopausal women. Two small prospective studies found
similar oestradiol levels in women who subsequently
developed breast cancer and control women (Garland et al.,
1992; Helzlsouer et al., 1994), but a large prospective study of
post-menopausal women found a significant increase in risk
associated with increased serum concentrations of oestradiol,
and particularly of free oestradiol (Toniolo et al., 1995).
The position is less clear among premenopausal women
(Key and Pike, 1988). Recent case-control studies have
reported higher oestradiol levels in cases than in controls
(Bernstein et al., 1990b; Zaridze et al., 1992). However, of the
two recent prospective studies with information for
premenopausal women, Helzlsouer et al. (1994) reported
higher follicular but lower luteal oestradiol in women who
subsequently developed breast cancer than in controls, while
Rosenberg et al. (1994) reported almost identical oestradiol
levels in cases and controls (although further adjustments for
stage of cycle by modelling suggested that oestradiol was on
average non-significantly higher in cases).
The results reported here are from a prospective study of
hormones and breast cancer on the island of Guernsey.
Previous analyses of this cohort have suggested that women
who subsequently develop breast cancer have a higher
proportion of serum oestradiol unbound to proteins (Moore
et al., 1986), but that breast cancer risk is not associated with
serum prolactin concentrations (Wang et al., 1992). In this
report we used the urine samples collected from women in the
Guernsey study to estimate urinary excretion of the three
classical oestrogens; oestrone, oestradiol and oestriol.
Subjet and meds
Subjects
Between 1977 and 1984, 5093 women aged 34 years and
above were recruited into a prospective study of hormones
and breast cancer on the island of Guernsey in the English
Channel. Height and weight were measured and a ques-
tionnaire was completed at interview with details of
reproductive history, menopausal status and use of oral
contraceptives and other hormonal therapy. A questionnaire
on cigarette smoking was given to the first 1213 women
recruited. A 24 h urine sample was collected; in premeno-
pausal women this sample was collected irrespective of the
stage of their menstrual cycle, but the dates of onset of
menses preceding and following urine collection were
recorded (the latter by postcard). The 24 h urine samples
were frozen at -200C and stored complete until aliquoting
during 1986 and 1987. A woman was classified as
premenopausal if she had menstruated in her usual pattern
in the previous 6 months and as post-menopausal if she had
not menstruated for 6 months or more.
Follow-up for the diagnosis of breast cancer was through
general practitioners, pathology reports (the island has only
one hospital and all pathology is dealt with by one consultant
pathologist), Guernsey death certificates and the Wessex
Cancer Registry.
Study design
Selection of urine samples for assay of oestrogens was made
in 1986. At that time two statistical analyses were planned:
one of the relationship of oestrogen excretion with breast
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cancer risk: the other of the relationship between oestrogen
excretion and cigarette smoking. For the planned analy sis in
relation to breast cancer. the samples selected for assav were
derived from all women who had developed breast cancer
subsequent to recruitment and before mid-1986 (n= 33).
together with up to ten controls per case (n=369). matched
by age and. in premenopausal women. by the number of days
between urine collection and the beginniung of their next
menstrual period. For the planned analysis of urinary
oestrogens in relation to cigarette smoking. the samples
selected for assay wAere those for all women who were current
smokers: for premenopausal women an additional selection
criterion was that urine samples had been collected either
between 3 and 11 days after the onset of the last
menstruation (follicular phase) or between 11 and 3 days
before the onset of the next menstruation (luteal phase).
Samples for comparison were from women who were known
to be non-smokers at recruitment but who met the other
criteria. randomly sampled to give a ratio of non-smokers to
smokers of approximately 2:1 among premenopausal women
and approximatelIy 3:1 among post-menopausal women. For
both planned analyses eligibility was restricted to women who
were premenopausal or naturally post-menopausal and were
not using exogenous sex hormones at the time of recruitment.
Owing to changing circumstances in the laboratories
involved, there was a delay of several years before all the
samples were aliquoted. sent to Melbourne and assayed (see
below). During this time new cases of breast cancer were
ascertained. both among controls in the planned matched
case-control study and among the women selected for the
planned study of the association of cigarette smoking with
oestrogen excretion. It was therefore decided to treat the 1000
women for whom assays were conducted as the total study
group and to conduct an unmatched analysis of urinary
oestrogens and breast cancer. using all cases of breast cancer
ascertained by December 1994.
Assays
Urine samples were considered to be incomplete if the 24 h
urine volume was less than or equal to 633 ml. the lower limit
of the 95/00 reference interval in 51 women studied by
Bingham et al. (1988). Aliquots of urine, identified by code
numbers. were sent frozen to the University of Melbourne.
where urinary concentrations of oestrone. oestradiol and
oestriol were measured during 1989 and 1990 using a method
involving spectrophotofluorimetrv and internal radioactive
standards (Brown. 1976). Assay variation was assessed bv
including one quality control sample. in each run of 12
samples. The mean values and coefficients of vanration for
this sample were: oestrone 9.8 pg L-'. 11%: oestradiol
3.7 pg L' 1 17/o0 oestnrol 7.2 jg L' . 14%. These coeffi-
cients of vanration incorporate both w'ithin-assay and
between-assay variability. Daily oestrogen excretion was
calculated from the concentration in the urine and the
volume of urine collected. Total excretion of oestrone.
oestradiol and oestriol was calculated as the sum of these
three oestrozens.
Statistical analysis
Oestrogen excretion rates were logarithmically transformed to
produce approximately normal distributions, and the mean
oestrogen values presented are geometric means. Adjustments
of means were made using analvsis of covariance for vear of
urine collection (see below), age (5 year age groups).
Quetelet's index (where stated: kg m- ) and. in premenopau-
sal women where stated. for stage of menstrual cycle (4 dav
categories: see below). The geometric means were calculated
to describe oestrogen excretion rates in cases and controls. To
examine the association of oestrogen excretion With breast
cancer risk we used unconditional logistic regression to
calculate odds ratios in thirds of the distribution of oestrogen
excretion rates in controls. and trend tests for the
logarithmically transformed continuous variables. Two-sided
P-values are quoted.
Association of oestrogen excretion with year ofblood collection
To assess whether there was evidence for deterioration of the
samples with long-term storage. we examined the association
of oestrogen excretion with the year of urine collection
(1977-84). adjusting for age and. in premenopausal women.
for the stage of the menstrual cycle (see below). In both
premenopausal and post-menopausal women there was a
statistically significant trend of higher oestrogen excretion in
the more recentlyf collected samples. The trends were
approximately linear and were similar for the three different
oestrogens. The estimated increases were 6.6% total
oestrogens per year in premenopausal women and 7.8P00
total oestrogens per year in post-menopausal women.
To minimise the impact of this effect on the results. year of
urine collection was included as a covariate in all subsequent
analyses. Adjustment for this variable had very little effect on
the case-control comparisons because the average year of
urme collection was almost identical in cases and controls.
Results
Characteristics of cases and controls
Among premenopausal women, cases and controls were
similar with respect to age. Quetelet's index, age at menarche
and panty: a greater proportion of cases than controls had
Table I Characteristics of cases and controls
I'ariable
Premenopausal
n
Age (years)
Quetelet's index (kg m-2)
Age at menarche (years)
Parous (Oo)
Oral contraceptisves (0o )C
Post-menopausal
n
Age (years)
Quetelet's index (kg m-2)
Age at menarche (years)
Parous (0O0)
Age at menopause (years)
Hormone use (0°0)9
Cases
Mean or %
38
41.7
24.4
13.1
87
74
31
58.3
26.3
13.5
68
50.7e
16
s.d. Mean or %
597
41.8
24.7
13.1b
91
58
4.2
3.4
1.5
5.7
3.3
2.0
3.4
334
57.8
25.4
13.3d
79
49.4'
20
Controls
s.d.
4.4
4.0
1.5
6.2
11 I
1.4
3.7
pa
0.933
0.676
0.911
0.629
0.078
0.669
0.194
0.503
0.203
0.068
0.742
aTwo-sided test for difference between means or proportions. bn= 595. 'Previous use of oral contraceptives. dn=331. n= 30. fn=36.
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previousy used oral contraceptives but this difference was not
statistically significant (Table I). Among post-menopausal
women, cases and controls were similar with respect to age,
age at menarche and hormone use; cases were slightly fatter,
less likely to be parous, and had a later menopause than
controls, but these differences were not statistically significant
(Table I).
Urinary oestrogen excretion in premenopausal women
Table H shows geometric mean total oestrogen excretion in
cases and controls, subdivided by the stage of the menstrual
cycle at which urine was collected. In both cases and controls
total oestrogen excretion was lowest in the early follicular
phase (20+ days before the end of the cycle), rising rapidly
to a peak at mid-cycle and then falling gradually during the
luteal phase. However, the increase in oestrogen excretion at
mid-cycle was less in the cases than in the controls. Similar
patterns were seen for the individual oestrogens.
Table III shows geometric mean oestrogen exccretion in
cases and controls, adjusted for the six cycle phase categories
used in Table II. Excretion of all three oestrogens was lower
in cases than in controls, and total oestrogen excretion was
15% lower (P=0.136). Further adjustment for age at
menarche, parity and previous use of oral contraceptives
did not substantially alter the results (data not shown).
Restriction of this analysis to the 34 cases diagnosed more
than 2 years after urine collection did not alter this result
(geometric mean total oestrogen excretion 15% lower in
cases, P=0.162; data not shown).
Table IV shows odds ratios for the risk of breast cancer
associated with three levels of oestrogen excretion as
determined by the tertiles of the distribution in controls.
For all three oestrogens risk decreased with increasing
oestrogen excretion, but the trends of decreasing risk were
not statistically significant.
Urinary oestrogen excretion in post-menopausal women
Table Ill shows geometric mean oestrogen excretion in post-
menopausal women. All values are adjusted for year of urine
collection and age, but the values are given before and after
further adjustments for Quetelet's index. Without adjust-
ments for this variable, geometric mean excretion of the three
oestrogens was 20-31% higher in cases than in controls,
with total oestrogen excretion 30% higher (P= 0.018).
Adjustment for Quetelet's index slightly reduced these
differences. Further adjustment for age at menopause did
not substantially alter the results (data not shown).
Restriction of this analysis to the 24 cases diagnosed more
than 2 years after urine collection did not alter the results
(geometric mean total oestrogen excretion, unadjusted for
Quetelet's index, was 33% higher in cases, P=0.022; data not
shown).
One case and two controls had total oestrogen excretion
greater than 50 jg 24 h-'. Exclusion of these three subjects
slightly reduced the difference between cases and controls:
geometric mean oestrogen excretion, unadjusted for Quete-
let's index, was 22% higher in cases, P=0.056.
For all three oestrogens the odds ratio for breast cancer
was highest in the top third of the distribution (Table IV).
These elevations in risk were not statistically significant, but
the trend in risk associated with increasing oestrogen
excretion was statistically significant for oestradiol
(P=0.022) andfor total oestrogens (P=0.016).
Discusion
The results for premenopausal women do not support the
hypothesis that breast cancer risk is increased by high
endogenous oestrogen levels, and indeed suggest that
average oestrogen excretion might be lower in cases than in
Table H Total oestrogen excretion by stage of menstrual cycle in premenopausal cases and controls
Cases Controls
Days until menstrualperid Geometric mean (95% CI) n Geometric mean (95% CI) n
20+ Follicular 12.9 (5.4-31.0) 2 13.1 (11.6-14.9) 95
16-19 20.2 (13.7-29.8) 10 23.4 (20.7-26.4) 102
12-15 Mid-cycle 25.8 (14.8-44.7) 5 36.0 (31.9-40.6) 104
8-11 ) 23.1 (16.4-32.5) 13 29.6 (26.7-32.8) 140
4-7 Luteal 18.2 (7.6-43.5) 2 26.8 (23.3-30.8) 78
0-3 29.6 (17.9-49.1) 6 24.4 (21.2-28.1) 78
Values are geometric means, ug 24h-I, adjusted for year of urine colection and age (<40,40-44,45 + years).
Table M oestrogen excretion in cases and controls
Cases Controls
Oestrogen Geometricmewan (95% CI) Geometric mean (95% CI) Pa
Premenopasat n=38 n=597
Oestrone 7.59 (6.15-9.36) 8.79 (8.34-9.27) 0.192
Oestradiol 3.95 (3.19-4.87) 4.53 (4.29-4.78) 0.22)
Oestriol 8.67 (6.82-11.02) 10.42 (9.81-11.07) 0.149
Total oestrogens 21.28 (17.43-25.99) 24.95 (23.72-26.24) 0.136
Post-menopausal n=31 n=334
Oestronec 1.78 (1.43-2.22) 1.48 (1.38-1.58) 0.121
Adjusted oestroned 1.73 (1.39-2.15) 1.48 (1.38-1.58) 0.185
OestradioF 0.98 (0.79- 1.23) 0.75 (0.70-0.80) 0.026
Adjusted oestradiol" 0.96 (0.77-1.20) 0.75 (0.70-0.81) 0.039
OestrioFc 2.01 (1.57-2.59) 1.61 (1.49-1.74) 0.101
Adjusted oestriold 1.92 (1.51-2.46) 1.62 (1.50-1.74) 0.187
Total oestrogenc 5.21 (4.26-6.38) 4.02 (3.78-4.27) 0.018
Adjusted total oestrogend 5.05 (4.14-6.15) 4.04 (3.80-4.29) 0.036
tTwo-sided test for difference between means.bValues are geometric means, pg 24h-I, adjusted for year ofurine collection, age(<40,40-44,
45+ years)anddayofthemenstrualcycleaturinecollection(0-3,4-7, 8-11, 12-15, 16-19,20+ days beforetheend ofthecycle). 'Values are geometric means, pg 24 If', adjusted for year of urine coLection and age (<55,55-59,60 + 'Vears). dalues are geometric means, pg 24 If',
adjusted for year ofurine collection, age (<55,55-59,60+ years) and Quetelet's index (kgm ).Urw _shoms and brast carmm
eO- TJA Key et al
Table IV Odds ratios (95% confidence intervals) for breast cancer in relation to urinary oestrogen excretion
Level ofoestrogen excretion
Oestrogen Cut points' Loweb Middle High Trendf
Premenopausafd
Oestrone 6.47, 12.35 1.0 0.5(0.2-1.2) 0.4(0.2-1.1) 0.216
Oestradiol 3.42, 6.23 1.0 0.8(0.4-1.8) 0.4(0.2-1.1) 0.263
Oestriol 7.27, 15.19 1.0 0.7(0.3-1.6) 0.7(0.3-1.6) 0.187
Total oestrogens 18.93, 34.63 1.0 0.9(0.4-2.0) 0.5(0.2-1.3) 0.165
Post-menopausal'
Oestrone 1.15, 1.82 1.0 0.9(0.3-2.2) 1.1(0.5-2.8) 0.111
Oestradiol 0.61, 0.96 1.0 0.8(0.3-2.3) 1.9(0.8-4.6) 0.022
Oestriol 1.26, 2.05 1.0 1.5(0.6-3.9) 1.8(0.7-4.6) 0.089
Total oestrogens 3.21, 4.90 1.0 0.9(0.4-2.6) 1.9(0.7-4.7) 0.016
aCut points for levels, pg 24 h-1. bReference. CP-value for linear trend forlogarithmically transformed continuous variable.dAdjusted foryear of
urinecollection, age (<40,40-44. 45 + years) and day ofcycleaturinecollection (0-3, 4-7, 8- 11, 12- 15, 16- 19, 20+ days before theend ofthe
cycle).'Adjusted for year of urine collection and age ( <55, 55 -59, 60 + years).
Table V Ratios of oestrogen levels in cases relative to oestrogen levels in controls, divided by phase of cycle
Follicular phase Luteal phase Both phases
First author Date Sanplea Cases Days Ratiob Cases Days Ratiob Cases Ratiob
Persson 1964 U 15 - 1.3 8 - 1.1
Marmorston 1%5 U 5 18-23 0.7
Argiielles 1973 U 47 14 0.7
England 1974 B 10 - > I 10 - >1
Malarkey 1977 B 5 - 0.9
Cole 1978 U 73 10 1.1 73 21 1.1
Sherman 1979 B 13 1.0
Drafta 1980 B 25 12-16 1.0 25 19-24 0.3
Moore 1982 B 32 1.1
MacMahon 1983 U 94 10 >1 94 21 >1
Bruning 1985 B 17 18-24 1.1
Meyer 1986 U 41 6 1.0 40 20-22 < I
Meyer 1986 B 36 20-22 > I
Siiteric 1986 B 36 1.1
Wysowskic 1987 B 17 0.8
Bemsteind 1990a B 39 22 1.2
Bernstein' 1990b B 42 22 1.1
Zaridze 1992 B 27 1.6
Helzlsouerf 1994 B 12 - 1.2 10 0.7
Rosenbergc 1994 B - 79 1.0
Key/ 1996 U 38 0.9
au, urine, oestrogen level taken as total oestrogens reported; B, blood(serum or plasma), oestrogen leveltaken as oestradiol. bRatio ofmean value
in cases to mean value in controls. cProspective study: the other studies are not prospective. dShanghai Chinese. 'Los Angeles whites.fCurrent study.
controls. There are too few cases to tell whether there is a
different pattern of oestrogen excretion during the menstrual
cycle in cases, but our results suggest that baseline levels in
cases (early follicular, late luteal) may be similar to those in
controls but that cases do not show as large a mid-cycle surge
as controls (Table II).
Table V shows the results of other studies (four
prospective, 16 case-control) of urinary or plasma oestro-
gens in premenopausal breast cancer cases and controls,
divided according to the stage of the cycle at which samples
were collected. The results are expressed as the ratio of the
mean value in cases to the mean value in controls. The
pattern is not consistent, but it may be noted that for all the
samples collected in the follicular phase the ratio of the mean
value in cases to that in controls was equal to or greater than
one, whereas for the luteal phase samples 6 out of the 14
ratios reported were less than one. The relationship of
oestrogen levels in premenopausal women with breast cancer
risk is still unclear, but future studies may benefit from
considering results in relation to the stage of the menstrual
cycle at which samples are collected.
For post-menopausal women, the current study supports
the evidence from prior studies suggesting that high oestrogen
levels are directly associated with breast cancer risk. The
differences between cases and controls were slightly reduced
by adjusting for Quetelet's index, as also reported by Toniolo
et al. (1995). However, because our hypothesis is that high
oestrogen levels in post-menopausal women increase breast
cancer risk, and that obesity is associated with risk because it
is one determinant of oestrogen levels (Grodin et al., 1973;
Judd et al., 1982), we do not think that it is appropriate to
adjust our results for Quetelet's index. We therefore conclude
that high levels of endogenous oestrogens are associated with
increased breast cancer risk in post-menopausal women.
One area of potential concern in the current study is the
method of selecting the study group of 1000 women for
whom assays were completed. As described above, this
comprised the sum of two studies planned in 1986, a
matched case-control study of breast cancer risk and a
study of the effects of cigarette smoking. Treating all these
subjects as one study group and conducting an unmatched
analysis of oestrogens and breast cancer risk gives the major
benefit of increasing the number of cases from 33 to 69. It
could be argued that the assembling of controls in two ways
might have introduced some bias. There is certainly some
overrepresentation of cigarette smoking among the controls
(29% current smokers among women with known smoking
status in this analysis, compared with 21% current smokers
among all women in the Guernsey cohort with known
smoking status), but analysis of the relationship of cigarette
smoking with urinary oestrogen excretion did not show any
differences in total oestrogen excretion (although there was a
19% reduction in excretion of oestriol (P=0.046) in post-
menopausal smokers; Key et al., in preparation). ToUrinary oestrogens and breast cancer
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investigate whether the structure of the study group may have
altered the results we also analysed the data according to the
original matching; the results were compatible with those
reported here, for example the odds ratios in the top third of
the distribution were 0.1, 0.1 and 0.5 for oestrone, oestradiol
and oestriol respectively in premenopausal women and 0.7,
1.4 and 1.8 in post-menopausal women, all with wide
confidence intervals. We think that it is likely that any
disadvantages of the method of assembling the study group
are outweighed by the advantage of the much larger number
of cases available in the unmatched analysis.
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